4 active not recruiting, 4 completed, 2 not yet recruiting, 2 recruiting. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Completed 2, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Tulisokibart: new trials by email Literature Review of Tulisokibart trials Research Report on Tulisokibart
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016) Tulisokibart, Placebo, Background prednisone therapy - Pulmonary Sarcoidosis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 158 | 2026-11-06 | 2026-10-09 |
| A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019) Tulisokibart, Placebo, Background prednisone therapy - Noninfectious Intermediate, Posterior, or Panuveitis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 87 | 2026-10-27 | 2026-10-06 |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) Tulisokibart, Placebo - Psoriatic Arthritis | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-20 | 2026-10-20 |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) Tulisokibart, Placebo, Methotrexate - Arthritis, Rheumatoid | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 185 | 2025-10-08 | 2026-09-24 |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) Tulisokibart, Placebo - Radiographic Axial Spondyloarthritis | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 315 | 2025-09-26 | 2026-10-23 |
| Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) Tulisokibart, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 149 | 2025-06-09 | 2026-10-02 |
| Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) Tulisokibart, Placebo to tulisokibart - Crohn Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1380 | 2024-11-25 | 2026-10-02 |
| Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) Tulisokibart - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 60 | 2024-09-24 | 2025-02-18 |
| Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) Tulisokibart, Placebo - Colitis, Ulcerative | Phase 1 | Completed | Merck Sharp & Dohme LLC | 48 | 2024-06-13 | 2025-02-17 |
| Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Tulisokibart, Companion diagnostic ( CDx), Placebo - Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease | Phase 2 | Active not recruiting | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 154 | 2022-03-29 | 2026-09-22 |
| A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) Tulisokibart, Companion Diagnostic (CDx) - Crohn Disease | Phase 2 | Completed | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 55 | 2021-07-28 | 2026-07-22 |
| A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo - Ulcerative Colitis | Phase 2 | Completed | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 178 | 2021-07-14 | 2026-09-01 |
Colitis, Ulcerative (3) · Crohn Disease (2) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Hidradenitis Suppurativa (1) · Lung Diseases, Interstitial (1) · Panuveitis (1) · Sarcoidosis, Pulmonary (1) · Scleroderma, Diffuse (1) · Severe combined immunodeficiency with sensitivity to ionizing radiation (1)
Merck Sharp & Dohme LLC (9) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3)
United States (9) · Canada (7) · Poland (7) · United Kingdom (6) · Chile (5) · France (5) · Germany (5) · Australia (4) · China (4) · Colombia (4) · Spain (4) · Belgium (3) · Czechia (3) · Georgia (3) · Hungary (3)
2025 (5), 2023 (3)